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ABSTRACT—Preclinical animal studies precede the majority of clinical trials. While the clinical definitions of sepsis and
recommended treatments are regularly updated, a systematic review of preclinical models of sepsis has not been done and
clear modeling guidelines are lacking. To address this deficit, a Wiggers-Bernard Conference on preclinical sepsis modeling
was held in Vienna in May, 2017. The goal of the conference was to identify limitations of preclinical sepsis models and to
propose a set of guidelines, defined as the ‘‘Minimum Quality Threshold in Preclinical Sepsis Studies’’ (MQTiPSS), to enhance
translational value of these models. A total of 31 experts from 13 countries participated and were divided into six thematic
Working Groups: Study Design, Humane modeling, Infection types, Organ failure/dysfunction, Fluid resuscitation, and
Antimicrobial therapy endpoints. As basis for the MQTiPSS discussions, the participants conducted a literature review of
the 260 most highly cited scientific articles on sepsis models (2002–2013). Overall, the participants reached consensus on 29
points; 20 at ‘‘recommendation’’ and nine at ‘‘consideration’’ strength. This Executive Summary provides a synopsis of the
MQTiPSS consensus. We believe that these recommendations and considerations will serve to bring a level of standardization

DOI: 10.1097/SHK.0000000000001212
Copyright ß 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf
of the Shock Society. This is an open access article distributed under the Creative
Commons Attribution License 4.0 (CCBY), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly
cited.

Address reprint requests to Dr Marcin F. Osuchowski, DVM, PhD, Ludwig
Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA
Research Center, Donaueschingenstrasse 13, A-1200 Vienna, Austria. E-mail: marcin.osuchowski@trauma.lbg.ac.at
CF controls the Claes Frostell Research & Consulting AB company that participated in supporting several clinical and experimental studies.
All other authors report no conflicts of interest.
Executive Summary

377

378

SHOCK VOL. 50, No. 4

OSUCHOWSKI

ET AL.

to preclinical models of sepsis and ultimately improve translation of preclinical findings. These guideline points are proposed as
‘‘best practices’’ for animal models of sepsis that should be implemented. To encourage its wide dissemination, this article is
freely accessible on the Intensive Care Medicine Experimental and Infection journal websites. In order to encourage its wide
dissemination, this article is freely accessible in Shock, Infection, and Intensive Care Medicine Experimental.
KEYWORDS—Antimicrobial therapy, experiment, fluid resuscitation, guidelines, humane modeling, infection types, organ
dysfunction, study design

‘‘This modeling thing, it’s pretty easy, but actually it’s also
really tough.’’ Cara Delevingne

THE NECESSITY
With the ultimate goal to reduce mortality/morbidity in
patients, animal modeling of diseases has been limited by poor
translation (1, 2). This is often fueled by the low fidelity of
available model systems (3, 4), their inappropriate study
designs (2) and selective use of animal data (5, 6). When
compared with other inflammatory states (e.g., arthritis, atherosclerosis), the complexity of sepsis has hampered the development of high-fidelity models. However, this challenge can be
aptly embraced by building on recent advances in the understanding of sepsis pathophysiology and avoiding past errors.
Any promising sepsis model must be specifically tailored to the
posited hypothesis, ‘‘reverse translated’’ to its clinical counterpart (7, 8), and adjusted as new pathophysiological evidence
emerges. This is echoed by the US Food and Drug Administration (FDA) in their 2010 Guidance for Industry and FDA
Staff: ‘‘FDA believes that the animal. . .(model). . .should provide a test system that offers a best attempt at simulating the
clinical setting.’’ (General Considerations for Animal Studies
for Cardiovascular Devices; www.fda.gov).
Unfortunately, while the clinical definition of sepsis is
currently in its third iteration (9) and the Surviving Sepsis
Campaign Guidelines for patient management have been
updated three times (10), preclinical sepsis research has not
been subjected to any organized attempt at introducing best
practices, management guidelines, and standardization (11).
This creates a large quality gap and confusion with conflicting
data reflecting huge variations in, for example, insult severity,
fluid resuscitation, and study duration. Effective animal modeling and reporting guidelines have recently been proposed for
other specific diseases such as pulmonary fibrosis (12), stroke
(13, 14), heart failure (15), and malaria (16) making the void in
the field of preclinical sepsis even more apparent. It is essential
that animal models of sepsis continue to evolve. Lack of
sufficient standardization of preclinical models will continue
to limit the utility of sepsis animal research as a useful platform
for advancing clinical outcomes and care in sepsis (17, 18) and
will reduce the opportunities to identify and test new therapies.
THE ACTION
To address this perceived deficit, the Ludwig Boltzmann
Institute of Experimental and Clinical Traumatology in the
AUVA Research Center organized in May 2017 in Vienna a
Wiggers-Bernard Conference on ‘‘Pre-clinical Modeling in
Sepsis: Exchanging Opinions and Forming Recommendations.’’

The key goal was to create publishable material that characterizes elements that should be included in preclinical sepsis
studies and defined by the so called ‘‘Minimum Quality Threshold in Pre-Clinical Sepsis Studies’’ (MQTiPSS) descriptor. The
Wiggers-Bernard Conference participants identified and
addressed several broad, critically-important concepts in animal sepsis modeling. A total of 31 experts from 13 countries
participated in the initiative (including five members of the
Sepsis-3 definitions task force) and were divided into six
thematic Working Groups: study design, humane endpoints,
infection types, organ failure/dysfunction, critical fluid resuscitation, and antimicrobial therapy.
The initiative consisted of three phases: preparatory (prior to
the meeting; approximately 3 months), during which participants
performed a systematic review of the 260 top cited (over 29,000
citations in aggregate) 2003 to 2012 preclinical publications
(using ISI Web of Knowledge database; query: ‘‘sepsis model’’;
374 individual experiments analyzed) and identified the key
modeling topics to be discussed, discussion during which the
participants spent two days at the Wiggers-Bernard Conference
examining preclinical sepsis models and ultimately voted to
reach consensus on the proposed points (either at the ‘‘recommendation’’ or ‘‘consideration’’ strength), and post-meeting
refinement of the accepted points and finalization of the arguments to be included in the final publications (using a modified
Delphi method; approximately three months). Following the
format used by the Sepsis-3 task force (8), at least 2/3 (over
65%) of the votes were required for approval of a proposed point.
THE PROPOSED OUTCOME
First, a definition for an animal model of sepsis was formulated and (unanimously) approved: ‘‘An experimental animal
(mammal) model of sepsis should be defined as life-threatening
organ dysfunction caused by a dysregulated host response to an
infection.’’ Second, Wiggers-Bernard Conference participants
reached consensus on 29 points; 20 at ‘‘recommendation’’
strength and nine at ‘‘consideration’’ strength (listed in
Tables 1–3). All consensus points were reached either unanimously or with no more than two abstentions per point (point
8). The ‘‘recommendation’’ strength indicates virtually unanimous agreement among the 31 participants, regarding both the
content and the need for rapid implementation. Issues that
require additional discussion before final recommendations
could be made were classified as considerations.
The current executive summary briefly describes the
Wiggers-Bernard Conference initiative and presents the compiled consensus points. The details of the recommendations/
considerations are published in three separate papers (19–21)
subsequently appearing in the 2019 January issue of Shock.
Tables 1–3 summarize the main MQTiPSS consensus points
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TABLE 1. Combined recommendations and considerations from the working group (WG) 1 and 2
Study design
(WG-1)

Humane modeling
(WG-2)

1.
2.
3.
4.
a.

Survival follow-up should reasonably reflect the clinical time course of the sepsis model.
Therapeutic interventions should be initiated after the septic insult replicating clinical care.
We recommend that the treatment be randomized and blinded when feasible.
Provide as much information as possible (e.g., ARRIVE guidelines) on the model and methodology, to enable replication.
Consider replication of the findings in models that include comorbidity and/or other biological variables (i.e., age,
gender, diabetes, cancer, immuno-suppression, genetic background, and others).
b. In addition to rodents (mice and rats), consider modeling sepsis also in other (mammal) species.
c. Consider need for source control.

R

5. The development and validation of standardized criteria to monitor the well-being of septic animals is recommended.
6. The development and validation of standardized criteria for euthanasia of septic animals is recommended
(exceptions possible).
7. Analgesics recommended for surgical sepsis consistent with ethical considerations.
d. Consider analgesics for nonsurgical sepsis.

R

C

C

R indicates recommendation strength; C, consideration strength.

TABLE 2. Combined recommendations and considerations from the working group (WG) 3 and 4
Infection types
(WG-3)

Organ failure/
dysfunction
(WG-4)

8. We recommend that challenge with LPS is not an appropriate model for replicating human sepsis.
9. We recommend that microorganisms used in animal models preferentially replicate those commonly found in
human sepsis.
e. Consider modeling sepsis syndromes that are initiated at sites other than the peritoneal cavity (e.g., lung, urinary
tract, brain).

R

10. Organ/system dysfunction is defined as life threatening deviation from normal for that organ/system based on
objective evidence.
11. Not all activities in an individual organ/system need to be abnormal for organ dysfunction to be present.
12. To define objective evidence of the severity of organ/system dysfunction, a scoring system should be developed,
validated and used, or use an existing scoring system.
13. Not all experiments must measure all parameters of organ dysfunction but animal models should be fully exploited.
f. Avoid hypoglycaemia.

R

C

C

R indicates recommendation strength; C, consideration strength.

TABLE 3. Combined recommendations and considerations from the working group (WG) 5 and 6
Fluid resuscitation
(WG-5)

Antimicrobial
therapy
(WG-6)

14. Fluid resuscitation is essential unless part of the study.
15. Administer fluid resuscitation based on the specific requirements of the model.
16. Consider the specific sepsis model for the timing of the start and continuation for fluid resuscitation.
17. Resuscitation is recommended by the application of iso-osmolar crystalloid solutions.
g. Consider using predefined endpoints for fluid resuscitation as deemed necessary.
h. Avoid fluid overload.

R

18. Antimicrobials are recommended for preclinical studies assessing potential human therapeutics.
19. Antimicrobials should be chosen based on the model and likely/known pathogen.
20. Administration of antimicrobials should mimic clinical practice.
i. Antimicrobials should be initiated after sepsis is established.

R

C

C

R indicates recommendation strength; C, consideration strength.

published in those articles: Part I—Table 1 content (19), Part
II—Table 2 (20), and Part III—Table 3 (21). Each publication
is built on two (related) Working Group themes and includes a
narrative clarifying caveats and intricacies related to the
accepted consensus points.

THE FUTURE
The presented consensus has not received formal endorsement from professional bodies. Writing an initial consensus

was a strategic decision given that an expert opinion report has
a shorter publication turnaround and our intention was to
rapidly introduce the MQTiPSS concept. The Wiggers-Bernard
Conference was conceived not as a one-time event but rather as
an initial ‘‘call-to-arms’’; an invitation to interested parties to
provide further refinement and expansion of the proposed
points. The on-going expansion initiatives include formation
of a Task Force (under the auspices of the Shock Society;
June 2017) for creation of robust, defined parameters to score
sepsis models for clinical relevance. Another iteration of the
Wiggers-Bernard Conference on animal sepsis models is
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planned for October 2019 at the joint conference of the
European Shock Society and International Federation of Shock
Societies in Crete, Greece.
In summary, we believe that the proposed guidelines
represent the first concrete steps toward creation of a realistic framework for standardization of animal models of
sepsis (i.e., MQTiPSS). Such a framework, once widely
employed, will improve the quality of preclinical investigation and arm clinicians with better tools for combating sepsis
in patients.
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